At Amunix, we have developed a novel half-life extension technology based on XTEN, a hydrophilic, unstructured polypeptide which can be recombinantly fused or chemically conjugated to other peptides, proteins, and small molecules. We have applied our XTEN technology platform to targets in a wide range of therapeutic areas, creating new protein pharmaceuticals characterized by improved efficacy, safety, and dosing.

Biogen Idec Signs License Agreement with Amunix for XTENylated Factor VIII

April 21, 2014 – Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license agreement to research and develop novel, fully-recombinant Factor VIII products with improved therapeutic properties.  Under the terms of the option agreement, Amunix will receive an upfront $1 million payment and will also be eligible to receive up to $38 million in clinical and commercial milestone payments.  In addition, royalties will be paid on commercial sales by Biogen Idec for Factor VIII products incorporating Amunix proprietary XTEN technology.

Amunix Announces Expansion to Licensing Agreement with Janssen for Its Proprietary XTEN Technology

January 7, 2014 – Amunix Operating Inc. (Amunix) announced today that Janssen Biotech, Inc. (Janssen) has expanded its existing worldwide research collaboration and licensing agreement with Amunix, increasing the number of available options for potential products. Under the terms of the agreement, Amunix will combine its XTEN half-life technology with the additional therapeutic molecules selected by Janssen over the duration of the agreement. Janssen will be responsible for all preclinical and clinical development as well as for manufacturing and commercialization of all resulting products.